The purpose of the Administration, Evaluation and Planning Core is to ensure the coordination of the Dana- Farber/Harvard Cancer Center (DF/HCC) Lung Cancer SPORE components and to provide oversight and leadership of the scientific, administrative, and fiscal aspects of the SPORE.Within the DF/HCC Lung Cancer SPORE, there are several layers of oversight and evaluation. Dr. Johnson, as SPORE Director, monitors the progress of the Projects and Cores and oversees the Career Development Program (along with Drs. David Christian! and Daniel Tenen), the Developmental Research Program (along with Dr. David Kwiatkowski), and all other proposed activities. Within the DF/HCC, Dr. Johnson has the authority and resources to ensure the success of this SPORE. Our Governance Committee, made up of senior members of the DF/HCC Lung Cancer Program, meets monthly to provide immediate decision-making. Dr. Johnson will be joined by David Christiani, Professor of Medicine and Public Health, to assume the responsibility as Co-Pi of the SPORE. Dr. Christiani brings his leadership expertise in pulmonary medicine and public health to our proposed studies in lung cancer. We have a strong Internal Advisory Board, comprised o f prominent members of the Harvard Medical School community and representing the participating institutions and major cancer research disciplines. Our External Advisory Board will meet in the Boston area annually during the five-year funding cycle. The membership and functions of these committees are discussed in detail in the description of this Core.The Administration, Evaluation and Planning Core allows for the provision of stimulating intellectual activities, organization of venues for planning future research through seminars and retreats, and the oversight of research and spending. This Core also provides the tools to work with institutions inside and outside of Harvard University to leverage the considerable power of the SPORE in order to raise more research funding for lung cancer. The responsibilities of the Administration, Evaluation and Planning Core are to: 1) Select research projects and evaluate research progress;2) Foster collaborative research within the SPORE and between SPOREs;3) Integrate the Lung SPORE into the DF/HCC structure;4) Provide necessary resources and fiscal oversight and 5) Promote rapid dissemination of significant research findings and facilitate resource exchange.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090578-10
Application #
8377871
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$619,944
Indirect Cost
$70,272
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Sofer, Tamar; Schifano, Elizabeth D; Christiani, David C et al. (2017) Weighted pseudolikelihood for SNP set analysis with multiple secondary outcomes in case-control genetic association studies. Biometrics 73:1210-1220
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672
Kinsey, C Matthew; San José Estépar, Raul; van der Velden, Jos et al. (2017) Lower Pectoralis Muscle Area Is Associated with a Worse Overall Survival in Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev 26:38-43
Rangachari, Deepa; VanderLaan, Paul A; Shea, Meghan et al. (2017) Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma. J Thorac Oncol 12:878-883
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
VanderLaan, Paul A; Rangachari, Deepa; Mockus, Susan M et al. (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer 106:17-21
Rangachari, Deepa; Le, Xiuning; Shea, Meghan et al. (2017) Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12:e175-e177
Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2017) Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium. Sci Rep 7:825

Showing the most recent 10 out of 256 publications